Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 15.82 is 46% above its 5-year average of 10.81, around the middle of its 5-year range (0.85–30.14).
As of the fiscal period ended Tuesday, June 30, 2026. 11.59% below its 12-month average of 17.90.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 15.82.
CURRENT RATIO
15.82
CURRENT RATIO AVG TTM
17.90
CURRENT RATIO AVG 3Y
11.63
CURRENT RATIO AVG 5Y
10.81
CURRENT RATIO AVG 10Y
6.15
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-11.59%
CURRENT VS 3Y AVG
+36.07%
CURRENT VS 5Y AVG
+46.39%
CURRENT VS 10Y AVG
+157.21%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.49
median of 700 covered companies
CURRENT VS SECTOR MEDIAN
+354.03%
vs the sector median at left
Inhibikase Therapeutics, Inc.
Market Cap
$263.39M
Current Ratio
15.82
TTM Avg
17.90
3Y Avg
11.63
5Y Avg
10.81
Market Cap
$264.62M
Current Ratio
13.89
TTM Avg
8.37
3Y Avg
7.38
5Y Avg
15.00
Market Cap
$267.17M
Current Ratio
16.00
TTM Avg
13.11
3Y Avg
8.33
5Y Avg
7.81
Market Cap
$267.82M
Current Ratio
8.88
TTM Avg
8.27
3Y Avg
7.75
5Y Avg
6.94
Market Cap
$258.56M
Current Ratio
4.48
TTM Avg
4.80
3Y Avg
5.23
5Y Avg
5.23
Market Cap
$256.22M
Current Ratio
8.28
TTM Avg
3.73
3Y Avg
7.03
5Y Avg
8.20
Market Cap
$271.23M
Current Ratio
4.50
TTM Avg
8.35
3Y Avg
6.79
5Y Avg
6.91
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | $263.39M | 15.82 | 17.90 | 11.63 | 10.81 |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $264.62M | 13.89 | 8.37 | 7.38 | 15.00 |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | 24.26 | 16.09 | 10.56 | 7.83 |
| AC Immune S.A. (ACIU)vs › | $260.03M | 0.93 | 1.36 | 5.78 | 8.29 |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $267.17M | 16.00 | 13.11 | 8.33 | 7.81 |
| OraSure Technologies, Inc. (OSUR)vs › | $267.82M | 8.88 | 8.27 | 7.75 | 6.94 |
| Anika Therapeutics, Inc. (ANIK)vs › | $258.56M | 4.48 | 4.80 | 5.23 | 5.23 |
| Century Therapeutics, Inc. (IPSC)vs › | $256.22M | 8.28 | 3.73 | 7.03 | 8.20 |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $271.23M | 4.50 | 8.35 | 6.79 | 6.91 |
| Quantum-Si incorporated (QSI)vs › | $252.22M | 9.97 | 9.81 | 16.34 | 20.09 |
Current Ratio
15.82
Quick Ratio
15.82
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 15.82 |
| 2026-03-31 | 30.14 |
| 2025-12-31 | 21.70 |
| 2025-09-30 | 11.73 |
| 2025-06-30 | 10.09 |
| 2025-03-31 | 11.01 |
| 2024-12-31 | 26.37 |
| 2024-09-30 | 0.85 |
| 2024-06-30 | 2.32 |
| 2024-03-31 | 2.55 |
| 2023-12-31 | 4.13 |
| 2023-09-30 | 6.40 |
| 2023-06-30 | 8.04 |
| 2023-03-31 | 10.37 |
| 2022-12-31 | 6.59 |
| 2022-09-30 | 8.71 |
| 2022-06-30 | 7.56 |
| 2022-03-31 | 8.76 |
| 2021-12-31 | 10.47 |
| 2021-09-30 | 16.94 |
| 2021-06-30 | 25.73 |
| 2021-03-31 | 3.31 |
| 2020-12-31 | 3.13 |
| 2020-09-30 | 0.01 |
| 2020-06-30 | 0.01 |
| 2020-03-31 | 0.01 |
| 2019-12-31 | 0.01 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
| 2018-12-31 | 0.35 |
| 2018-03-31 | 0.13 |
| 2017-12-31 | 0.11 |
| 2017-03-31 | 0.00 |
